


Supplementary Material

Supplementary Table 1 Dose distribution of fruquintinib or regorafenib among the four groups


Drug doses	n (%)
F (n=70)	
4mg	5 (7.1)
5mg	65 (92.9)
FP (n=95)	
3mg	8 (8.4)
4mg	2 (2.1)
5mg	85 (89.5)
R (n=67)	
80mg	15 (22.4)
120mg	35 (52.2)
160mg	11 (16.4)
Unknown	6 (9.0)
RP (n=81)	
80mg	36 (44.4)
120mg	31 (38.3)
160mg	12 (14.8)
Unknown	2 (2.5)

Supplementary Material




Supplementary Figure 1A The subgroup analysis of PFS in the fruqintinib group

Supplementary Material




Supplementary Figure 1B The subgroup analysis of OS in the fruquintinib group

Supplementary Material




Supplementary Figure 1C The subgroup analysis of PFS in the FP group

Supplementary Material




Supplementary Figure 1D The subgroup analysis of OS in the FP group

Supplementary Material




Supplementary Figure 1E The subgroup analysis of PFS in the regorafenib group

Supplementary Material




Supplementary Figure 1F The subgroup analysis of OS in the regorafenib group

Supplementary Material



Supplementary Figure 1G The subgroup analysis of PFS in the RP group

Supplementary Material



Supplementary Figure 1H The subgroup analysis of OS in the RP group